Behavioral and Cognitive Therapies for Auditory Hallucination Management

University Hospital, Toulouse55 enrolled

Overview

The present study wants to evaluate the efficacy of a short psychoeducational type group intervention and Cognitive behavioral therapy (CBT) 3rd wave on the severity of hallucinatory Acoustico-Verbal (HAV) symptomatology in patients with schizophrenia.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Psychosis

Interventions

Behavioral and Cognitive TherapiesBEHAVIORAL

Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave "Accept Voices" applied to HAV

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Schizophrenic disorders, schizo-affective disorders * Suffering from persistent HAV * No change in symptomatology for 3 months. * No anticipated change in antipsychotic treatment (anti-hallucinatory): olanzapine, risperidone, amisulpride, quetiapine, aripiprazole, loxapine, haloperidol, clopixol, modecate, nozinan, cyamemazine, piportil, clozapine * Major patient, or major incompetent. Exclusion Criteria: * Mental retardation * Subject participating in another search including an exclusion period still in progress at pre-inclusion

Locations (5)

Lannemezan Hospital

Lannemezan, France

Lavaur Hospital

Lavaur, France

Sainte-Marie de Rodez Hospital

Rodez, France

Ariège-Couserans Hospital

Saint-Lizier, France

Gérard Marchand Hospital

Outcomes

Primary Outcomes

intensity HAV symptoms

Difference between the Psychotic Symptom Rating Scales (PSYRATS) on HAV symptom score administered before the first therapeutic group session and the PSYRATS symptom score administered 1 week after the last group session. The PSYRATS Scales measure dimensions of hallucinations and delusions.

Time frame: Baseline and one week after the last session

Secondary Outcomes

Effect over time

Difference between the PSYRATS score given 1 week before the first session, and the PSYRATS score administered one week after the last session and then at 6 weeks, 6 months and 12 months.

Time frame: Until 12 months after the last session

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.